XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update

XOMA Royalty Corporation (NASDAQ:XOMA) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 824,924 shares, a growth of 56.7% from the December 31st total of 526,343 shares. Currently, 7.2% of the company’s shares are sold short. Based on an average daily volume of 869,075 shares, the short-interest ratio is currently 0.9 days. Based on an average daily volume of 869,075 shares, the short-interest ratio is currently 0.9 days. Currently, 7.2% of the company’s shares are sold short.

XOMA Royalty Stock Performance

NASDAQ XOMA opened at $25.66 on Friday. The firm has a market cap of $317.67 million, a P/E ratio of 34.68 and a beta of 0.89. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The company’s 50 day moving average is $27.76 and its 200-day moving average is $31.16. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The firm had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. Sell-side analysts predict that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Buying and Selling at XOMA Royalty

In other news, CEO Owen Hughes purchased 100,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were acquired at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the transaction, the chief executive officer owned 102,000 shares of the company’s stock, valued at $2,555,100. The trade was a 5,000.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 9.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Woodline Partners LP boosted its position in XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after buying an additional 12,284 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of XOMA Royalty in the 2nd quarter valued at about $370,000. Geode Capital Management LLC boosted its holdings in XOMA Royalty by 9.1% during the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after acquiring an additional 16,929 shares during the period. JPMorgan Chase & Co. grew its position in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in XOMA Royalty by 18.0% in the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 2,019 shares during the period. 95.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Zacks Research lowered XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 18th. UBS Group set a $76.00 target price on XOMA Royalty in a report on Tuesday, December 9th. Benchmark reissued a “buy” rating on shares of XOMA Royalty in a research report on Friday, December 12th. Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Finally, Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a research note on Friday, December 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $60.60.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.